The U.S. Food and Drug Administration (FDA) has approved a major label expansion for Ionis Pharmaceuticals’ Tryngolza (olezarsen), allowing the therapy to be used to treat adults with severe hypertriglyceridemia (sHTG). The decision significantly broadens the drug’s commercial potential, transforming it from a treatment for a rare genetic disorder into one that addresses a much larger patient population at risk of acute pancreatitis.
Summary
- The FDA has expanded Tryngolza’s approval to include adults with severe hypertriglyceridemia (sHTG).
- The therapy is the first FDA-approved treatment specifically indicated to reduce both triglycerides and the risk of acute pancreatitis in sHTG patients.
- Severe hypertriglyceridemia affects an estimated 3.6 million people in the United States.
- Ionis plans to initially focus on approximately 500,000 patients at the highest risk of pancreatitis.
- The approval significantly expands the commercial opportunity for Tryngolza beyond its original rare disease indication.
The FDA approved Tryngolza as an adjunct to diet for adults with severe hypertriglyceridemia, defined as triglyceride levels of 500 mg/dL or higher. In addition to lowering triglyceride levels, the therapy is now indicated to reduce the risk of acute pancreatitis, making it the first treatment specifically approved for both objectives in this patient population.
Tryngolza was originally approved in December 2024 to treat familial chylomicronemia syndrome (FCS), an ultra-rare inherited disorder that prevents the body from properly breaking down fats. While that initial indication served only a few thousand patients in the United States, the new approval opens access to a substantially larger market. According to Ionis, approximately 3.6 million Americans have severe hypertriglyceridemia, although the company intends to initially focus on roughly 500,000 patients whose triglyceride levels exceed 880 mg/dL and who face the greatest risk of pancreatitis.
Severe hypertriglyceridemia is characterized by extremely high concentrations of triglycerides in the bloodstream. In addition to increasing cardiovascular risk, the condition can trigger acute pancreatitis, a painful and potentially life-threatening inflammation of the pancreas that often requires hospitalization and can lead to permanent organ damage. Patients who experience one pancreatitis episode face a higher likelihood of recurrent attacks.
The FDA’s decision was supported by data from two Phase 3 clinical trials evaluating monthly doses of Tryngolza in patients with severe hypertriglyceridemia. In one study, patients receiving the 80 mg monthly dose achieved a placebo-adjusted triglyceride reduction of up to 72% after six months, while the 50 mg dose produced reductions of approximately 63%. A second trial involving patients with somewhat lower triglyceride levels demonstrated reductions of 55% and 49% for the two dosing groups, respectively.
The studies also demonstrated significant improvements in additional clinical outcomes. According to Ionis, 86% of patients receiving Tryngolza reduced their triglyceride levels below 500 mg/dL, a threshold associated with a lower risk of pancreatitis, while more than half of treated patients achieved normal triglyceride levels. Researchers also reported an 85% reduction in pancreatitis risk as a secondary endpoint during the clinical program.
Tryngolza is an RNA-targeted antisense oligonucleotide therapy designed to reduce production of apolipoprotein C-III (apoC-III), a liver protein that plays a key role in regulating triglyceride metabolism. By lowering apoC-III levels, the therapy enhances the body’s ability to clear triglyceride-rich lipoproteins from the bloodstream, resulting in substantial reductions in circulating triglycerides.
The approval represents an important commercial milestone for Ionis Pharmaceuticals. The company began independently commercializing medicines only in 2024 following the initial launch of Tryngolza for FCS. Sales of the therapy reached approximately $108 million during its first full year on the market, exceeding the company’s initial expectations. Earlier this year, Ionis increased its projected peak annual sales estimate for Tryngolza from $2 billion to $3 billion in anticipation of approval in the broader severe hypertriglyceridemia population.
To prepare for the expanded indication, Ionis substantially reduced Tryngolza’s list price earlier this year, lowering it by approximately 93% ahead of negotiations with insurers. The company said the pricing strategy was intended to improve patient access while aligning with payer contracting cycles before the anticipated FDA decision.
Ionis has also expanded its commercial organization in preparation for the launch. The company’s sales team has been educating endocrinologists, cardiologists, and lipid specialists about the treatment since February, positioning the drug for broader adoption following the approval.
The expanded approval strengthens Ionis’ position in the growing market for RNA-targeted medicines while establishing Tryngolza as the first therapy specifically approved to both lower triglycerides and reduce the risk of acute pancreatitis in adults with severe hypertriglyceridemia. For the company, the decision marks a significant step in transitioning from a rare disease-focused biotechnology developer into a commercial pharmaceutical company targeting much larger patient populations.
Ionis has achieved an important regulatory milestone after the U.S. Food and Drug Administration (FDA) expanded the approval of Tryngolza for the treatment of severe hypertriglyceridemia. The expanded indication strengthens Ionis’ position in the cardiovascular and metabolic disease market while providing a new treatment option for patients at risk of complications associated with extremely high triglyceride levels.
The approval reflects continued progress in the development of innovative RNA-targeted therapies designed to address serious lipid disorders.
Ionis Secures Expanded FDA Approval
The FDA’s expanded approval allows Ionis to offer Tryngolza to a broader group of patients diagnosed with severe hypertriglyceridemia. The decision was supported by clinical evidence demonstrating the therapy’s ability to significantly reduce triglyceride levels while maintaining an acceptable safety profile.
This regulatory achievement represents another important step in Ionis’ ongoing efforts to develop treatments for rare and complex diseases.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
